Dr. Reddy’s Laboratories Limited shares are expected to remain in focus after the pharmaceutical company announced the launch of its generic Semaglutide Injection in Canada, marking a significant step in its global expansion within the fast-growing GLP-1 therapy segment.
The company introduced the product shortly after receiving approval from Health Canada, highlighting its focus on accelerating access to affordable diabetes and obesity-related treatments in regulated international markets.
Generic Semaglutide Injection Launched in Canada
According to the company, the newly launched generic Semaglutide Injection will be available in a pre-filled pen format. The product will be offered in two dosage strengths — 2 mg per pen and 4 mg per pen.
Semaglutide belongs to the GLP-1 (Glucagon-Like Peptide-1) class of therapies, which has witnessed substantial global demand growth in recent years due to increasing prevalence of diabetes, obesity, and metabolic disorders.
The launch strengthens Dr Reddy’s growing portfolio of complex injectable and peptide-based therapies across global healthcare markets.
Focus on Expanding Access to GLP-1 Therapies
Dr Reddy’s stated that the launch demonstrates the company’s readiness to expand patient access to affordable GLP-1 treatment options internationally.
Commenting on the development, Chief Executive Officer Erez Israeli said the company successfully launched the product within days of receiving regulatory approval from Health Canada, reflecting its capabilities in complex drug development and peptide manufacturing.
The company has been steadily increasing its focus on high-value specialty therapies, biosimilars, injectables, and regulated market expansion as part of its broader global growth strategy.
GLP-1 Segment Emerging as Major Pharma Growth Area
The GLP-1 drug category has become one of the fastest-growing segments in the global pharmaceutical industry. Demand for these therapies has surged due to their increasing use in diabetes management as well as weight management and obesity treatment.
Global pharmaceutical companies are actively expanding their presence in this segment through new product launches, manufacturing investments, and regulatory approvals across multiple geographies.
For Indian pharmaceutical companies, the segment also presents opportunities to strengthen their footprint in regulated markets such as North America, Europe, and Canada.
Share Price Movement
As of May 18, 2026, at 10:15 AM, Dr Reddy’s share price was trading at ₹1,331.60 per share, down 0.38% from the previous closing level.
Summary
Dr Reddy’s Laboratories has launched its generic Semaglutide Injection in Canada shortly after receiving Health Canada approval. The product will be available in pre-filled pen formats with 2 mg and 4 mg strengths. The launch marks an important milestone in the company’s strategy to expand its presence in the rapidly growing global GLP-1 therapy market and strengthen its international diabetes care portfolio.
Disclaimer:
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.
